Skip to main
  1. Stocks
  2. Enovis Corp
  3. Forecast
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is supported by solid 3Q26 execution, with revenue of $558.7M, 4.6% organic growth, adjusted EBITDA of $104M, and non-GAAP EPS of $0.88 all beating consensus while margins expanded meaningfully. Its outlook is strengthened by a favorable product mix and share gains in higher-growth Reconstructive offerings such as Nebula, ARVIS, and shoulder and extremities, alongside steadier Prevention & Recovery cash flow from bracing, Recovery Sciences, and BoneStim. Free cash flow of $35M, leverage falling to 2.9x from 3.1x, a raised 2026 EBITDA and EPS outlook, and a new $200M buyback all signal improving financial quality and shareholder-friendly capital allocation.

Bears say

Enovis is facing a negative outlook because its growth profile remains too dependent on Prevention & Recovery, where low-single-digit growth is offset by softer Western European volumes, tariff pressure, Middle East conflict, and a roughly 180 bps revenue headwind from the Dr. Comfort divestiture. Management’s FY26 guidance only implies $2.32B-$2.35B of revenue and $428M-$438M of adjusted EBITDA, while the eCential Robotics acquisition is expected to dilute adjusted EBITDA margin by about 150 bps in 2027, underscoring integration and dilution risk. Competitive pressure in reconstructive surgery, slower-than-expected market share gains, and continued operating margin contraction could keep earnings below expectations and limit valuation support.

Enovis Corp (ENOV) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Enovis Corp (ENOV) Analyst Forecast & Price Prediction

Get the latest Enovis Corp (ENOV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Enovis Corp (ENOV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Enovis Corp (ENOV) Analyst Forecast & Price Prediction

Get the latest Enovis Corp (ENOV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Enovis Corp (ENOV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ENOV stock data and trends